Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Norway

Innovation Action · Running

PREDI-LYNCH Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH Syndrome

Coordinator
Oslo Universitetssykehus Hf, Norway
Runs
1 May 2025 to 30 April 2031
Status
Running
EU funding
€13.6m
Total cost
€14.0m
Partners
30 organisations in 16 countries
Type
Innovation Action
Grant agreement
101213916

What the project is doing

In the project's own words, from its summary on CORDIS.

We propose an ambitious yet well-conceived and deliverable pan-European, pan-cancer, pan-disciplinary, and multi-omic approach to address the pressing unmet need for an accurate, non-invasive, acceptable and cost-effective method of detecting precancerous and early-stage cancers in those individuals with Lynch syndrome (LS), the most common monogenetic increased hereditary cancer risk. LS has historically been underfunded and underserved, leading to significant an inequality in access and treatment.

As a result, LS carriers have suffered needless cancers and deaths as a result. Our consortium has brought together the leading European experts, biotechnology companies and patient advocates to guarantee deliver practice-changing results that can be rapidly upscaled and adopted across the European Union and globally. Using an innovative clinical trial design, we will evaluate several multiple promising, non-invasive, liquid biopsy-based technologies in the three most common LS cancer types for an early-stage cancers detection.

By leveraging Artificial intelligence (AI), we will identify traces of cancer, ensuring applicability to diverse healthcare systems. A comprehensive framework will assess the broader socio-economic and ethical impacts, ensuring that the solutions align with the societal values and healthcare needs. Parterning with leading biomarker companies (GNT, MSInsight, MSICare, MSIPlus and Elypta), we aim to deliver a multi-omic solution for affordable, accessible and effective test to advance the detection of heritable cancer detections in LS.

This action is part of the Cancer Mission cluster of projects on “Prevention & early detection (early detection heritable cancers).

Who is involved

OrganisationCityCountryRole
Oslo Universitetssykehus HfOsloNorwayCoordinator
European Regional and Local Health Authorities ASBLEtterbeekBelgiumParticipant
Udg AllianceLausanneSwitzerlandAssociatedpartner
Masarykuv Onkologicky UstavBrnoCzechiaParticipant
Eit Health eVMunchenGermanyParticipant
Semi-Colon e.V.MönchengladbachGermanyParticipant
Predictby Research and Consulting S.l.BarcelonaSpainParticipant
Universidad De GranadaGranadaSpainParticipant
Tampereen Korkeakoulusaatio SrTampereFinlandParticipant
Institut CurieParisFranceParticipant
Institut Gustave RoussyVillejuifFranceParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
MSInsightParisFranceParticipant
Protisvalor Mediterranee SASMarseilleFranceThird party
UnicancerParisFranceParticipant
Universite D'aix MarseilleMarseilleFranceParticipant
Klinicki Bolnicki Centar Sestre Milosrdnice UstanovaZagrebCroatiaParticipant
Fondazione Irccs Istituto Nazionale Dei TumoriMilanItalyParticipant
Rigas Stradina UniversitateRigaLatviaParticipant
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsParticipant
Universiteit UtrechtUtrechtNetherlandsParticipant
Oslo Cancer Cluster SAOsloNorwayParticipant
Universitetet I OsloOsloNorwayParticipant
Associacao Evita - Cancro HereditarioLisboaPortugalParticipant
Europacolon Portugal- Associacao De Luta Contra O Cancro Do IntestinoPortoPortugalParticipant
I3s - Instituto De Investigacao E Inovacao Em Saude Da Universidade Do PortoPortoPortugalParticipant
Elypta ABSolnaSwedenParticipant
Geneton S.r.o.BratislavaSlovakiaParticipant
The University of EdinburghEdinburghUnited KingdomParticipant
University of Newcastle Upon TyneNewcastle Upon TyneUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI